Instruction for use: Insulin zinc suspension, compound (Insulini cum Zinco suspensio composita)

Pharmacological group

Insulins

Composition and form of release

1 ml of the suspension for injection contains insulin of a pig high purity monocomponent 40 U (unit of action) and 1 mg of methyl parahydroxybenzoate, as a preservative; In glass bottles of 10 ml, in a cardboard bundle 1 bottle.

Characteristic

Monocomponent highly purified porcine insulin containing 30% amorphous and 70% crystalline insulin. The white suspension, upon standing, is stratified to form a white precipitate and a clear colorless or almost colorless supernatant, the precipitate is easily suspended with slight shaking.

pharmachologic effect

Pharmacological action - hypoglycemic.

It lowers the level of glucose in the blood, increases its absorption by tissues, activates glycogenogenesis, synthesis of protein and lipids, inhibits lipolysis, glycogenolysis and conversion of amino acids into glucose.

Clinical Pharmacology

The preparation of insulin of average duration of action. The effect develops 2.5 hours after the SC administration, reaches a maximum in the range of 7-15 hours and lasts for 24 hours.

Indications

Diabetes mellitus (type 1) in children and adults, diabetes mellitus (type 2) (in the case of resistance to oral hypoglycemic drugs, including partial for combination therapy, against intercurrent diseases, during pregnancy).

Contraindications

Hypersensitivity, hypoglycemia.

Side effects

Hypoglycemia (pallor of the skin, increased sweating, palpitation, tremor); Allergic reactions (skin rash, rarely - angioedema, extremely rare - anaphylactic shock); Hyperemia, itching, lipodystrophy (with prolonged use) at the injection site.

Interaction

MAO inhibitors, nonselective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine, preparations containing ethanol increase hypoglycemic effect; Oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations, tricyclic antidepressants - weaken. Reserpine and salicylates can both weaken and enhance hypoglycemic action.

Dosing and Administration

P / to, the dose is determined individually, before use, the bottle is gently shaken. The drug must be entered immediately after typing in the syringe. A daily dose exceeding 0.6 U / kg should be administered as two or more injections in different areas of the body.

Overdose

Symptoms: a sharp increase in sweating, palpitation, tremor, hunger, excitement, paresthesia in the mouth, pallor, headache; In severe cases - hypoglycemic coma.

Treatment: ingestion of sugar or foods rich in carbohydrates; In severe cases - the introduction of glucose (20-40 ml 40% solution iv) and glucagon (1 mg IM).

special instructions

Patients receiving more than 100 units / day Brinsulmidi MK, when changing the drug, it is advisable to hospitalize.

The transition from one type of insulin to another should be carried out under the control of blood glucose.

At primary appointment, change of a kind of insulin or occurrence during treatment of stressful situations the ability to control vehicles and mechanisms, to other potentially dangerous kinds of activity demanding increased attention and speed of mental and motor reactions is possible.

When changing the nature and diet, significant physical exertion, infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison's disease, hypopituitarism, renal insufficiency, and in patients older than 65 years, the dosage should be adjusted.

Insulin lowers tolerance to alcohol.

storage Conditions

In the dark place at a temperature of 2-8 ° C. Do not freeze.

Keep out of the reach of children.

Shelf life

2.5 years.

Do not use after the expiry date printed on the package.